BOTALYS receives €2,2M grant from European Commission

Belgian producer of rare medicinal plants BOTALYS earns the trust of the European Commission and is granted a hyper-competitive subsidy of €2.2 million euros.

Within the framework of the Horizon 2020 programme, BOTALYS (formerly known as Green2Chem) was selected amongst 1752 candidatures from 37 countries for the SME Instrument Phase 2 funding. This is the second time that Botalys benefits from the support of the European Commission. 

In 2017, the Belgian company already received the SME Instrument Phase 1.

Horizon 2020 is the largest research and innovation programme of the European Union for the 2014-2020 period. It aims at encouraging European innovation and favour the emergence of future leaders capable of improving tomorrow’s world through the excellence of their expertise and know-how. Chances of obtaining subsidies are extremely limited: a mere 3 to 5%!

BOTALYS joins the ranks of 15 Belgian companies - including only 3 from Wallonia - having obtained a SME Instruments Phase 2 subvention to date for a total amount of €26.4 million euros. The success of this project would not have been possible without the intervention and judicious advice of NCP Wallonie and ZAZ Ventures, both experts in supporting applicants for the H2020 Programme.

BOTALYS developed a highly-innovating technology destined to the culivation of rare plants. This European funding follows a recent €3 million euros fundraising.

The company can now pursue the international deployment of its first product, hydroponic Ginseng HRG80®, which was developed in the aim of offering the best ginseng in the world and to accelerate its R&D to rapidly offer new and rare medicinal plants.

After six years of research and development, BOTALYS’ team of researchers successfully developed a unique process based on the principle of hydroponics, an off-ground cultivation technique that consists in controlling every cultivation parameter. Hydroponics allows for optimal nutrient inputs in ideal conditions (oxygen, pH...). In this way, the growth of the plant is optimised to offer an exceptional and constant quality finished ingredient devoid of toxic residue or solvent. This technique also allows preserving the natural resources of our planet by avoiding excessive and intensive agriculture (pesticides, fungicides...) and a massive deforestation typical of rare, difficult to cultivate plants. All of BOTALYS’ plants are grown in Belgium by respecting the world’s strictest standards in social and environmental matters.   

BOTALYS’ plants reach an exceptional standard of quality thanks to their unique purity which translates in remarkable results demonstrated in consumer tests already carried out for BOTALYS’ Ginseng.


BOTALYS is a Belgian producer of rare plants and ingredients that are beneficial to health by minimising the ecological impact on the planet. BOTALYS developed a unique technology in the world based on vertical cultivation hydroponics that allows producing natural and highly efficient ingredients such as the HRG80®, the market’s premium ginseng. No pesticides, solvents or enzymes are used during production. BOTALYS’ clients include key players of the nutraceutic, cosmetic, food and medical markets wishing to offer their consumers the purity and force of nature, ethically. Created in 2011 under the name Green2Chem, BOTALYS currently boasts 9 collaborators and will double its effective before end 2019.

Scientific tests completed:


Related news

events, blog or press release

  • img tyls

    BOTALYS earns FSSC 22000 certification

    NEWS • 21.11.2019 •